TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Cutaneous oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median of the System Usability Scale (SUS) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median Score of the mHealth App Usability Questionnaire (MAUQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Perception of Disease Worsening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Examination time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of the refined interventions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of the refined interventions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Muscle oxygen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bilirubin levels estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Anti-tumors efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean reduction of RV/LV ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in viral loads
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of complicated hospital stay
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of HES flares
Endpoint domain: Adverse events/effects
Primary endpoint: Change in psychosocial distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in vision-related quality-of-life (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in health-related QoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of participants completing at least 2 cycles of iTTo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED recidivism
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Clinician review of PGx results
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: MD Anderson Symptom Inventory-Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Overall Quality of Ocular Comfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Anxiety Score Using the Visual Analogue Score for Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Anxiety Score Based on The Amsterdam Preoperative Anxiety and Information Scale (APAIS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Secondary adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change in Serum Potassium Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 20-month progression free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Study related adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: The AGI score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean Change from Baseline for Average Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean Crohn's disease Activity Index (CDAI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants achieving endoscopic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thiamin plasma concentrations (AUC0-24 hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Occurrence of Any Major Adverse Cardiovascular Event (MACE-4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Apparent clearance of drug from plasma after drug administration (CL/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to infinity (AUC-infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration of pretomanid (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician Administered Dissociative Symptoms Scale (CADSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CogState Battery
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Knee Osteoarthritis Outcomes Scale (KOOS) pain subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Opioid Misuse
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Posttraumatic Stress Disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 6-Min Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Handgrip strength test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Enrolled Participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of Intervention Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of patients enrolling in clinical trials
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Post-operative infectious episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Monocular photopic DCIVA (first eyes) at 66 cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocular Depth of Focus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocular Photopic BCDVA at 4m
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocular Photopic DCVA at 100 cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral health related attitude
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: The 6 Minute Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Indifference points
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total expenditures on fruits and vegetables
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Change in Quality of Life Questionnaire - CIPN20 Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants Achieving Lupus Low Disease Activity State (LLDAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of assigned female at birth (AFAB) participants with microbiologic cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of assigned male at birth (AMAB) participants with microbiologic cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return to golf following joint arthroplasty
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Visual Analogue Patient Satisfaction Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tilburg Pregnancy Distress Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prenatal Self-Assessment Scale- Fear of Birth and Birth Readiness Sub-Dimensions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quantity of Tobacco Products Purchased in the High-Tax Tier
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Quantity of Tobacco Products Purchased in the Medium- and No-tax tiers
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Poly-tobacco purchasing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean percentage change in Ki-67
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Width of the alveolar bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height of bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Width of bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of daily re-irradiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma letermovir AUC24 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonatal plasma acyclovir mean AUC12 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Speed to Initiate Avoidance Behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Select Device-related Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in the risk of the overall warning level for abnormal ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of complete lesion healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Late Gastrointestinal (GI) Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in log10 P. aeruginosa total colony counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of grade 2 or higher treatment-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Positive identification of viruses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prognostic markers for progression of sepsis to septic shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Discontinued From Study Treatment due to Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants who complete the post-treatment visit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants who rate the intervention a 16 or more on the Client Satisfaction Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants who score above threshold (34 or more) on the mHealth Satisfaction Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subject incidence of Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Subject incidence of Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Reduced Left Ventricular Ejection Fraction (LVEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Δ Mean AUC Plasma Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of ibuzatrelvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of ibuzatrelvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUClast) of ibuzatrelvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of completing visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Qualitative experience at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Qualitative experience at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of participants with Complete Renal Response (CRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of participants achieving definition of remission in SLE (DORIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of UroLift implant
Endpoint domain: Adverse events/effects
Primary endpoint: End of induction minimal residual disease negative remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Dose Limiting Toxicity (DLT)-like events
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic (PK) Plasma Concentrations of M9466
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in FEV1 Area Under the Curve (AUC0-12h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Non-hierarchical composite endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brachial artery flow-mediated dilation (percent vasodilation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ICU-free days in the first 28 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seizure networks power spectrum medians
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Seizure networks total volume medians
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of GERD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Level of awareness of esophageal cancer risk factors and alarm symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of anticipated and unanticipated Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change from average baseline in morning trough FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy of zimberelimab +/- domvanalimab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Occurrence of Major Adverse Cardiac Event (MACE)-4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Primary handwriting kinematic parameter (velocity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ALS Functional Rating Scale-Revised (ALSFRS-R)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: ALS Functional Rating Scale-Revised Self entry (ALSFRS-RSE)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Subjects reaching Investigator's Global Assessment (IGA) success - Seborrheic dermatitis (SD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in lesion count Papulopustular Rosacea (PPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the Curve from Zero to Infinity (AUC [0 to ∞]) of Mirikizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the Curve from Zero to Time to Last Concentration (AUC [0 to tlast]) of Mirikizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of changes from baseline in haematology, biochemistry, and urinalysis parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean change in PHQ-9 to assess depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean change in Perceived Stress Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean change in Zarit Caregiver Burden 6-item version
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Mean change in Caregiver Self-Efficacy Scale (CSES-8)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean change in UCLA Loneliness Scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Mean change in Social Network Scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Number of participants discontinuing study therapy due to AE
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the plasma concentration-time curve from dosing to 24 hours postdose (AUC0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Hemoglobin A1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Memory Experiences Questionnaire (MEM-Q)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Occurrence of any drug-related, treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Absolute change from baseline in forced expiratory volume in 1 second, percent of predicted value (FEV1pp)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to clinical progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline Fixation stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline Saccadic re-referencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence of tumor-antigen specific T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Older adult quality of life (self-report)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Older adult quality of life (proxy-report)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Insight impairment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: PTSD Screen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Spike rates per hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Seizure frequency per night
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in autism program quality
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hyperglycemic Events
Endpoint domain: Adverse events/effects
Primary endpoint: Brain Age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Lead complication-free rate at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects successfully defibrillated at implant with the Next Generation ICD lead
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lead-related major complication rate at 3-months
Endpoint domain: Adverse events/effects
Primary endpoint: Time to onset of labor analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to first event of Cardiovascular death
Endpoint domain: Mortality/survival
Primary endpoint: Time to hospitalisation for heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to urgent heart failure visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Drug adherence/Pill Counts
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Provider engagement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Degree of head turn
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term safety of GV-971
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Area under the Pain Curve (AUPC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility Measure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Utility Measure
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Engagement Measure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in the average score of the degree of individual symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the average score of the frequency of individual symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of high SSTR2 expression in tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Feasibility of the software
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety of the software
Endpoint domain: Adverse events/effects
Primary endpoint: Respiratory-support-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline in Brief Pain Inventory (BPI) Score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Incidence of any treatment-emergent adverse events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: bleeding free probability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence, severity, seriousness, and dose relationship of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: 50% reduction in the apnea hypopnea index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Satisfactory pain response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of neutrophil engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes